JPRN-UMIN000018412已完成未知
Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors" - JACCRO CC-13AR
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 227
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients who are regarded as inadequate for study enrollment by investigators. (2) Patients who refuse to supply the section.
研究者
相似试验
已完成
不适用
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancerliver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancerJPRN-UMIN000010429EPS Corporation100
尚未招募
2 期
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic CancerCTRI/2008/091/000081Hoffmann-La Roche200
招募中
不适用
A biomarker research of "A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer "Colorectal cancerJPRN-UMIN000034885Japan Clinical Cancer Research Organization (JACCRO)80
招募中
不适用
A biomarker assessment study to investigate the influence of high-frequency chest wall oscillations on the clearance of cerebrospinal fluid biomarkersNL-OMON51372Centre for Human Drug Research34
招募中
不适用
An exploratory prospective study of the biomarkers of the immune-related adverse events (irAE) and the mechanisms of irAE in solid cancer patients treated with Pembrolizumab.solid cancerJPRN-UMIN000028474Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.30